Australia’s CSL reports strong performance led by Ig

Australian biotech CSL Limited (ASX: CSL) today reported revenue of A$14.8 billion (US$9.7 billion) for the 12 months ended June 30, 2024, up 11% at constant currency, driven by a 14% increase in total revenue reported by the CSL Behring business.

Net profit after tax (NPATA) of A$2.64 billion1 for the 12 months was, up 25% on a constant currency basis. NPATA was A$2.91 billion, up 15% on a constant currency basis to A$3.01 billion. CSL’s shares closed down 4.6% at A$294.78.

The company forecast statutory net profit after tax between A$3.2 billion and A$3.3 billion on a constant currency basis for the 2025 financial year, a rise of up to 13% from 2024, buoyed by strong performance at its plasma products manufacturing business. However, the forecast fell short of the Visible Alpha consensus of A$3.39 billion.